Enriquez A, Bolisetty S, Patole S, Garvey P A, Campbell P J
Department of Newborn Care, Royal Hospital for Women, Randwick New South Wales, Australia.
Arch Dis Child Fetal Neonatal Ed. 1998 Sep;79(2):F110-3. doi: 10.1136/fn.79.2.f110.
To assess the efficacy of cisapride in reducing the time required to establish enteral feeds in preterm infants.
A randomised, double blind, placebo controlled trial was conducted of 34 infants of < or = 32 weeks of gestation, assigned to receive either cisapride 0.2 mg/kg/dose four times daily (n = 18) or placebo (n = 16).
The time taken by the babies to tolerate full enteral feeds was not significantly different between the groups (median 9.5 days vs 10 days). There was a significantly lower incidence of large gastric residuals and regurgitation in the treated group compared with the placebo group. The number of episodes of large gastric residuals per infant was also significantly less. No adverse effects were noted.
The routine use of cisapride in preterm infants cannot be recommended to decrease the time to establish enteral feeds. Its use may be justified for clinically significant gastric stasis or regurgitation.
评估西沙必利在缩短早产儿建立肠内喂养所需时间方面的疗效。
对34例孕周小于或等于32周的婴儿进行了一项随机、双盲、安慰剂对照试验，这些婴儿被分配接受每日4次、每次0.2 mg/kg西沙必利治疗（n = 18）或安慰剂治疗（n = 16）。
两组婴儿耐受完全肠内喂养所需时间无显著差异（中位数分别为9.5天和10天）。与安慰剂组相比，治疗组大胃残余物和反流的发生率显著降低。每个婴儿的大胃残余物发作次数也显著减少。未观察到不良反应。
不建议常规使用西沙必利来缩短早产儿建立肠内喂养的时间。对于临床上明显的胃潴留或反流，使用西沙必利可能是合理的。
